Brief: Aytu Biopharma Announces Fast Track Designation Granted To AR101
19/04/2022 13:28
April 19 (Reuters) - Aytu Biopharma Inc AYTU.O :
* AYTU BIOPHARMA ANNOUNCES FAST TRACK DESIGNATION GRANTED TO
AR101
FOR THE TREATMENT OF VASCULAR EHLERS-DANLOS SYNDROME
* AYTU BIOPHARMA INC- PLANS TO BEGIN PATIENT DOSING BY LATE
2022
OR EARLY 2023
Source text for Eikon: ID:
Further company coverage: AYTU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aytu Biopharma
See all newsAytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary
Aytu BioPharma Q4 revenue beats analyst estimates on EXXUA sales
Aytu Biopharma Inc expected to post a loss of 32 cents a share - Earnings Preview
Aytu BioPharma Q3 revenue falls amid EXXUA launch
Aytu BioPharma Q2 revenue beats expectations